Related Experiment Videos
Erythropoietin in heart failure
Donald S Silverberg1, Dov Wexler, Miriam Blum
1Department of Nephrology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. donald@netvision.net.il
Seminars in Nephrology
|November 22, 2005
Summary
Anemia worsens heart failure and kidney disease, creating a cardio-renal-anemia syndrome. Treating anemia with erythropoietin and iron improves heart function, kidney health, and quality of life.
Area of Science:
- Nephrology
- Cardiology
- Hematology
Background:
- Congestive heart failure (CHF) and end-stage renal disease (ESRD) are increasing.
- Anemia is prevalent in CHF and chronic kidney insufficiency (CKI), worsening mortality and morbidity.
- A vicious cycle, termed the cardio-renal-anemia syndrome, links CHF, CKI, and anemia.
Purpose of the Study:
- To investigate the impact of anemia on CHF and CKI.
- To evaluate the efficacy of anemia correction in patients with CHF and CKI.
Main Methods:
- Observational analysis of patients with CHF and CKI.
- Treatment of anemia using subcutaneous erythropoietin and intravenous iron.
Main Results:
- Anemia correction significantly improved CHF symptoms, cardiac function, and reduced hospitalizations.
- Renal function stabilized or improved in most patients after anemia treatment.
- Erythropoietin may offer direct cardioprotective and neuroprotective benefits beyond anemia correction.
Conclusions:
- The cardio-renal-anemia syndrome highlights the interconnectedness of heart failure, kidney disease, and anemia.
- Anemia treatment is crucial for managing CHF and CKI, improving patient outcomes and quality of life.
- Erythropoietin holds potential therapeutic value in cardiovascular and renal diseases.